TY - JOUR
T1 - Extracellular vesicle therapeutics from plasma and adipose tissue
AU - Iannotta, Dalila
AU - Yang, Man
AU - Celia, Christian
AU - Di Marzio, Luisa
AU - Wolfram, Joy
N1 - Funding Information:
This work is partially supported by the Mayo Clinic Center for Regenerative Medicine in Florida , USA (JW), the National Institute of Allergy and Infectious Diseases , National Institutes of Health , USA under award number R21AI152318 (JW), the American Heart Association , USA under award number 20TPA35490415 (JW), the Italian Ministry of Education , University and Research , Italy, under the national project Programma Operativo Nazionale Ricerca e Innovazione ( PON ) 2014–2020 ( CCI 2014IT16M2OP005 ) Fondo Sociale Europeo, Azione I.1, Dottorati Innovativi con Caratterizzazione Industriale (DI, JW, LDM), and China Scholarship Council , China (MY). The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies. Fig. 3 a was made in ©BioRender - biorender.com .
Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/8
Y1 - 2021/8
N2 - Extracellular vesicles (EVs) are cell-released lipid-bilayer nanoparticles that contain biologically active cargo involved in physiological and pathological intercellular communication. In recent years, the therapeutic potential of EVs has been explored in various disease models. In particular, mesenchymal stromal cell-derived EVs have been shown to exert anti-inflammatory, anti-oxidant, anti-apoptotic, and pro-angiogenic properties in cardiovascular, metabolic and orthopedic conditions. However, a major drawback of EV-based therapeutics is scale-up issues due to extensive cell culture requirements and inefficient isolation protocols. An emerging alternative approach to time-consuming and costly cell culture expansion is to obtain therapeutic EVs directly from the body, for example, from plasma and adipose tissue. This review discusses isolation methods and therapeutic applications of plasma and adipose tissue-derived EVs, highlighting advantages and disadvantages compared to cell culture-derived ones.
AB - Extracellular vesicles (EVs) are cell-released lipid-bilayer nanoparticles that contain biologically active cargo involved in physiological and pathological intercellular communication. In recent years, the therapeutic potential of EVs has been explored in various disease models. In particular, mesenchymal stromal cell-derived EVs have been shown to exert anti-inflammatory, anti-oxidant, anti-apoptotic, and pro-angiogenic properties in cardiovascular, metabolic and orthopedic conditions. However, a major drawback of EV-based therapeutics is scale-up issues due to extensive cell culture requirements and inefficient isolation protocols. An emerging alternative approach to time-consuming and costly cell culture expansion is to obtain therapeutic EVs directly from the body, for example, from plasma and adipose tissue. This review discusses isolation methods and therapeutic applications of plasma and adipose tissue-derived EVs, highlighting advantages and disadvantages compared to cell culture-derived ones.
KW - Adipose tissue
KW - Extracellular vesicles
KW - Isolation methods
KW - Plasma
KW - Therapeutic
UR - http://www.scopus.com/inward/record.url?scp=85104965780&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85104965780&partnerID=8YFLogxK
U2 - 10.1016/j.nantod.2021.101159
DO - 10.1016/j.nantod.2021.101159
M3 - Review article
AN - SCOPUS:85104965780
SN - 1748-0132
VL - 39
JO - Nano Today
JF - Nano Today
M1 - 101159
ER -